Suven Life Sciences announced that the company is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their lead compound SUVN-502 at Neuroscience 2018, organized by Society for Neuroscience being held at San Diego, USA during 4 to 7 November 2018.

Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 30 thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this conference.

Shares of the company gained Rs 0.65, or 0.27%, to trade at Rs 237.40. The total volume of shares traded was 42,838 at the BSE (12.02 p.m., Monday).